The sale of its proteomic tools business to Bio-Rad may be in a holding pattern, but Ciphergen is already touting itself as a diagnostics firm.
 
One week after the anticipated Nov. 1 completion date, the sale of Ciphergen’s Surface Enhanced Laser Desorption/Ionization technology and other products to Bio-Rad still remained delayed. But in comments to analysts this week, Ciphergen CEO Gail Page made it clear that the company is forging ahead in its new identity as a specialty diagnostic firm.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.